Camptodactyly–Arthropathy–Coxa Vara–Pericarditis (CACP) Syndrome: A Comprehensive Disease Characteristics Report

Disease: Camptodactyly–Arthropathy–Coxa Vara–Pericarditis Syndrome MONDO ID: MONDO:0008828 · OMIM: 208250 · Causal gene: PRG4 (lubricin / proteoglycan 4) Category: Mendelian (autosomal recessive)

Summary

Camptodactyly–Arthropathy–Coxa Vara–Pericarditis (CACP) syndrome is an ultra-rare, autosomal recessive Mendelian disorder caused by biallelic loss-of-function mutations in PRG4, the gene encoding lubricin (also known as proteoglycan 4, superficial zone protein, or megakaryocyte-stimulating factor precursor). Lubricin is a large secreted, mucin-like glycoprotein that provides boundary lubrication to articular cartilage and serosal (pericardial, pleural, tendon-sheath) surfaces and simultaneously suppresses the overgrowth of synovial intimal cells. When lubricin is absent, two coupled pathological processes occur: friction-driven death of superficial-zone chondrocytes and uncontrolled synovial intimal hyperplasia. Together these drive the disease's characteristic non-inflammatory tetrad: congenital camptodactyly (flexion contractures of the fingers), early-childhood non-inflammatory large-joint arthropathy with synovial hyperplasia, progressive coxa vara with a short femoral neck, and non-inflammatory serosal (pericardial/pleural) effusions.

A central clinical theme — recurring across essentially every modern case series — is that CACP is repeatedly misdiagnosed as juvenile idiopathic arthritis (JIA) and treated, ineffectively, with NSAIDs, methotrexate, corticosteroids, and biologic TNF inhibitors. The key distinguishing features are persistently normal inflammatory markers (ESR/CRP), non-inflammatory synovial fluid (low white-cell count), absence of erosions on imaging, and the presence of coxa vara/short femoral neck. Definitive diagnosis is made by PRG4 sequencing (whole-exome/whole-genome or single-gene), which typically reveals homozygous (or compound heterozygous) truncating variants in consanguineous families, supported by an antibody-based assay showing lubricin absence in blood and synovial fluid.

There is no approved disease-modifying treatment; management is supportive (physiotherapy, orthopedic correction of coxa vara, joint replacement for end-stage disease, pericardiectomy for constrictive pericarditis). The most mechanistically rational investigational therapy is recombinant human PRG4 (rhPRG4) replacement, supported by preclinical large-animal and in vitro data. Prognosis is dominated by progressive joint deformity/disability, with cardiac serositis (constrictive pericarditis) representing the principal life-threatening complication; cognition and lifespan are otherwise generally preserved.

Key Findings

Finding 1 — CACP is caused by biallelic loss-of-function mutations in PRG4 (lubricin)

CACP was mapped and cloned by positional-candidate methods to chromosome 1q25–q31, where mutations in a gene designated CACP (now PRG4) encoding a secreted proteoglycan were identified as the cause of the autosomal recessive syndrome (PMID: 10545950): "we identified mutations in a gene (CACP) encoding a secreted proteoglycan as the cause of CACP." PRG4 had previously been identified independently as the precursor of megakaryocyte-stimulating factor and as the articular cartilage "superficial zone protein," unifying several research threads under one gene.

Across subsequent case series the inheritance mechanism is uniform: biallelic loss-of-function variants. A large cohort of 13 Indian patients explicitly states the syndrome "is caused by biallelic loss-of-function variants in PRG4" (PMID: 38856641), and multiple independent reports describe homozygous truncating variants such as c.1290del (p.T431Lfs*481) in consanguineous families (PMID: 40874560).

Gene annotation: HGNC PRG4; OMIM gene 605602; OMIM phenotype 208250. Suggested MONDO: MONDO:0008828.

Finding 2 — Mechanism: lubricin lubricates cartilage AND restrains synovial overgrowth; its loss produces friction-driven chondrocyte apoptosis plus synovial hyperplasia

Lubricin has a dual protective role, and CACP pathology reflects the loss of both functions. In lubricin-mutant mice, abnormal protein deposits accumulate on the cartilage surface, superficial-zone chondrocytes are lost, and — critically — "intimal cells in the synovium surrounding the joint space became hyperplastic, which further contributed to joint failure. Purified or recombinant lubricin inhibited the growth of these synoviocytes in vitro" (PMID: 15719068). This single observation explains both the cartilage failure and the synovial hyperplasia that clinically mimics inflammatory arthritis.

The friction–apoptosis link is mechanistically demonstrated: lubricin-knockout joints show elevated whole-joint friction and increased chondrocyte apoptosis, and in a bovine cartilage-on-cartilage explant system "we observed a direct correlation between coefficient of friction and chondrocyte apoptosis in the superficial layers of cartilage," an effect reversed by adding lubricin (PMID: 23530215). Downstream, friction induces chondrocyte mitochondrial dysregulation and caspase-3 activation (PMID: 28604608), identifying apoptosis as the terminal tissue-damage step.

Suggested GO/CL terms: GO:0006915 (apoptotic process), GO:0005615 (extracellular space), GO:0008285 (negative regulation of cell proliferation); CL:0000138 (chondrocyte), CL:0000214 (synovial cell).

Finding 3 — The clinical tetrad is non-inflammatory and is frequently misdiagnosed as JIA

CACP presents as a tetrad: congenital/early-onset camptodactyly, childhood-onset non-inflammatory arthropathy with synovial hyperplasia, progressive coxa vara, and non-inflammatory pericardial (± pleural) effusion (PMID: 40830943). Phenotype frequencies from the 13-patient Indian cohort are: "Camptodactyly (13/13), coxa vara (11/13), short femoral neck (11/13) and arthritis in large joints (12/13)" (PMID: 38856641), with wrists (11/13), ankles (11/13), elbows (10/13) and knees (10/13) most affected.

Because synovial hyperplasia superficially resembles inflammatory arthritis but inflammatory markers are normal and synovial fluid is non-inflammatory (low WBC), misdiagnosis as JIA is the rule rather than the exception. In one series "all patients were exposed to biologic therapy due to recalcitrant JIA" (PMID: 40475173), and multiple independent reports describe prolonged, ineffective immunosuppression before genetic confirmation (PMID: 41626297; PMID: 42074176; PMID: 42482035).

Suggested HPO terms: HP:0100490 (camptodactyly of finger), HP:0005750 (coxa vara), HP:0001367 (abnormal joint morphology), HP:0001644 (pericardial effusion), HP:0002102 (pleural effusion), HP:0100658 (joint effusion), HP:0100763 (synovial hypertrophy).

Finding 4 — Serosal (pericardial/pleural) involvement is variable, often later, and can be life-threatening

Pericarditis/pericardial effusion is the most variable and least penetrant element of the tetrad. It is described as occurring "rarely" in some cohorts (PMID: 40475173: "early-onset camptodactyly, noninflammatory arthropathy, coxa vara deformity, and, rarely, pericardial effusion"), reflecting lubricin's role on visceral serosal surfaces. When present and severe, it progresses to constrictive pericarditis requiring pericardiectomy, and has been misattributed to tuberculosis: "the elder sister had pericardial effusion with constrictive pericarditis, underwent pericardiectomy and received empirical treatment for suspected tuberculosis" (PMID: 38955384). Neonatal pleural effusion with respiratory distress followed by later pericardiectomy has also been reported (PMID: 40830943), and a unique association with mitral stenosis requiring commissurotomy was documented, hypothesized to relate to the proteoglycan content of the mitral valve (PMID: 38523390).

Finding 5 — No cure exists; management is supportive; rhPRG4 replacement is the rational investigational therapy

No approved disease-modifying treatment exists. Because the arthropathy is non-inflammatory, anti-inflammatory/immunosuppressive regimens fail: a patient "despite receiving treatment modalities such as non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, and corticosteroids... experienced minimal improvement" (PMID: 40830943). The mechanistically rational strategy is lubricin (rhPRG4) replacement: intra-articular full-length recombinant human PRG4 reduced cartilage damage in a Yucatan minipig model of medial-meniscus destabilization — "the rhPRG4 group had significantly less macroscopic cartilage damage in the medial tibial [plateau]" (PMID: 28129516) — and purified/recombinant lubricin inhibits synoviocyte overgrowth and reduces chondrocyte apoptosis in vitro (PMID: 15719068; PMID: 23530215). Supportive care includes physiotherapy, orthopedic correction of coxa vara (e.g., valgus osteotomy), joint replacement for end-stage arthropathy, and pericardiectomy for constrictive pericarditis.

Suggested NCIT terms: NCIT:C15431 (Physical Therapy), NCIT:C15329 (Surgery), protein replacement therapy (rhPRG4, investigational).

Finding 6 — Mutational spectrum: predominantly truncating (frameshift/nonsense) loss-of-function variants, with strong consanguinity/homozygosity

As of 2023 only "36 pathogenic mutations have been reported in this gene" (PMID: 36694203), underscoring the disease's rarity. The spectrum is overwhelmingly truncating:

The 13-patient Indian cohort reported "five novel disease-causing variants (c.3636G>T, c.1935del, c.1134dup, c.1699del and c.962T>A)" (PMID: 38856641). Variants are typically homozygous in consanguineous families, consistent with autosomal recessive inheritance. Most truncating variants are predicted to trigger nonsense-mediated decay or yield non-functional truncated protein (PMID: 40874560). Under ACMG/AMP these are generally classified pathogenic/likely pathogenic (null variant in a gene where LOF is the established mechanism).

Finding 7 — The Prg4-null mouse recapitulates key CACP features

The lubricin-deficient (Prg4⁻/⁻) mouse is the primary disease model. Mice are viable and fertile with normal joints at birth, then develop age-dependent cartilage-surface protein deposits, superficial-zone chondrocyte loss, synovial intimal hyperplasia, and periarticular pathology: "tendon and tendon sheath involvement was present in the ankle joints, where morphologic changes and abnormal calcification of these structures were observed" (PMID: 15719068) — relevant to the camptodactyly/contracture phenotype. Stereological analysis confirms deficient superficial/upper-intermediate-zone chondrocyte cellularity with caspase-3/TUNEL-positive apoptosis (PMID: 26975998). In the temporomandibular joint, "as early as 2 weeks of age, mutant mice exhibited hyperplasia in the glenoid fossa articular cartilage, articular disc, and synovial membrane" progressing to osteoarthritic degradation, ectopic cartilage, and mineralization (PMID: 24834922; PMID: 26945615; PMID: 26534931). Ectopic cartilage in Prg4-null TMJ discs is associated with excess BMP signaling and ectopic hedgehog signaling, candidate downstream pathways.

Finding 8 — Protein-level consequence: truncating mutations abolish lubricin synthesis/secretion; normal lubricin requires disulfide-dependent SPC processing

In patients carrying frameshift or nonsense PRG4 mutations, "the antiserum did not detect lubricin in synovial fluid or cultured synoviocytes from several patients with frameshift or nonsense mutations in PRG4" (PMID: 16000300) — direct evidence that the disease mechanism is loss of protein (absent synthesis/secretion). The same work showed that wild-type lubricin undergoes post-translational cleavage within its C-terminal hemopexin-like domain by a subtilisin-like proprotein convertase (SPC), and that "formation of an intrachain disulfide bond is required for SPC-mediated cleavage and that SPC-mediated cleavage is essential to protein function." Epitope mapping localizes key monoclonal-antibody epitopes to O-linked oligosaccharides on the mucin-domain KEPAPTTT motif (PMID: 25642942).

Finding 9 — Diagnostic biomarker: lubricin is absent from blood and synovial fluid, enabling an antibody-based test alongside sequencing

Epitope-specific anti-lubricin monoclonal antibodies (raised in Prg4⁻/⁻ mice) detect lubricin in healthy individuals but not in CACP patients: "the competition ELISA detected lubricin in blood samples from healthy individuals but not from patients with CACP, indicating blood can be used in a diagnostic test for patients suspected of having CACP" (PMID: 25642942). This provides a blood-based screening/confirmation assay. Definitive diagnosis remains PRG4 sequencing (WES/WGS/single-gene) (PMID: 38856641). Supporting distinguishing labs/imaging: normal ESR/CRP; non-inflammatory synovial fluid (gelatinous, viscous, low WBC, sterile — PMID: 41637065); musculoskeletal ultrasound shows marked synovial effusion and circumferential synovial hypertrophy without power Doppler activity (PMID: 41637065); radiographs show joint effusion/synovial debris without erosions, coxa vara, short femoral neck, and metaphyseal flaring (PMID: 42074176).

Finding 10 — Epidemiology/inheritance: ultra-rare autosomal recessive, consanguinity-linked, complete joint penetrance with variable expressivity, no strong sex bias

CACP is an ultra-rare monogenic autosomal recessive disorder (OMIM 208250) with no established population prevalence; only a few hundred cases and ~36 catalogued mutations are reported worldwide (PMID: 36694203). Cases cluster in consanguineous families and populations (Middle East, Turkey, South Asia, North Africa). The 13-patient cohort derived from "eight consanguineous Indian families" with 7 females and 6 males (PMID: 38856641), indicating no strong sex predilection. Penetrance of the joint phenotype is essentially complete in biallelic carriers, while expressivity — especially the cardiac/serosal component — is variable. Regionally, a Southeastern Turkey series identified CACP in 12 of 47 individuals evaluated for non-inflammatory musculoskeletal complaints mimicking rheumatic disease (PMID: 40626694), underscoring its relative frequency among genetic JIA mimics in consanguineous populations.

Finding 11 — Natural history/prognosis: congenital onset, chronic progressive non-inflammatory arthropathy; cardiac serositis is the main life-threatening risk; cognition and lifespan usually preserved

Onset is congenital/early (camptodactyly at birth/infancy; arthropathy in early childhood). The course is chronic and progressive: "deficiency of PRG4 results in progressive worsening of joint deformity with age" (PMID: 38856641), producing large-joint contractures, coxa vara/short femoral neck, and "precocious joint failure" (PMID: 15719068). Reduced bone mineral density has been reported as part of a broader phenotypic burden (PMID: 42482035). Serosal disease can present even in adulthood as a first episode of constrictive pericarditis and represents the principal cause of serious morbidity/mortality; most patients have normal intelligence and near-normal lifespan when cardiac disease is managed.

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic truncating mutation in PRG4 (frameshift/nonsense) leads to loss of full-length lubricin mRNA/protein via nonsense-mediated decay or non-functional truncated product (demonstrated: lubricin undetectable in patient synovial fluid/synoviocytes, 16000300).
2. Absent lubricin results in loss of boundary lubrication at articular cartilage and serosal surfaces, and in parallel loss of the normal inhibitory signal that restrains synovial intimal cell proliferation (demonstrated in mouse/in vitro, 15719068).

→ Branch A (cartilage/joint): - 3a. Loss of lubrication leads to an elevated coefficient of friction at the cartilage surface (demonstrated, 23530215; 28604608). - 4a. Increased friction results in superficial-zone chondrocyte mitochondrial dysregulation and caspase-3–mediated apoptosis, leading to depletion of superficial-zone chondrocytes and surface protein deposition (demonstrated, 23530215 26975998 28604608). - 5a. In parallel, de-repressed synovial intimal cells undergo hyperplasia, producing non-inflammatory synovial thickening and effusion (demonstrated, 15719068). - 6a. Progressive cartilage failure + synovial hyperplasia leads to precocious large-joint arthropathy, contractures (camptodactyly, inferred from tendon/sheath involvement), and, at the hip, coxa vara with short femoral neck (clinical, 38856641 15719068).

→ Branch B (serosa): - 3b. Absent lubricin on pericardial/pleural serosal surfaces leads to non-inflammatory serosal effusion, which can result in fibrosis/constrictive pericarditis (clinical, variable expressivity; 40475173 38955384).

Upstream vs downstream

• Upstream (initiating): PRG4-null genotype → absent lubricin protein.
• Midstream (mechanistic): increased friction + loss of synoviocyte growth inhibition.
• Downstream (effector): chondrocyte apoptosis, synovial hyperplasia, serosal effusion.
• Terminal (clinical): camptodactyly, arthropathy, coxa vara, pericarditis, reduced BMD.

Cell types, tissues, and compartments

Mechanistic nuances

• CACP is not inflammatory: synovial hyperplasia is a direct consequence of lost lubricin growth-inhibition, not immune-driven synovitis — explaining the universal failure of immunosuppression and the normal CRP/ESR.
• Mouse models reveal downstream signaling perturbations (ectopic hedgehog and excess BMP signaling driving ectopic cartilage/osteophytes in the TMJ; 26945615 26534931), which are candidate secondary pathways best characterized in the TMJ model rather than in human CACP tissue.

Evidence Base

Consistency: All human and model-organism evidence converges on a single, coherent loss-of-function mechanism. No source contradicts the core model; the main variability is clinical expressivity of the cardiac/serosal component.

Section-by-Section Compendium

1. Disease information. CACP (MONDO:0008828; OMIM 208250; ORPHA:1236). Synonyms: Camptodactyly-arthropathy-coxa vara-pericarditis syndrome; CACP syndrome; arthropathy-camptodactyly syndrome; familial arthropathy. Information is derived from aggregated disease-level case reports/series and model-organism studies (no large EHR datasets; the disease is ultra-rare).

2. Etiology. Purely genetic — biallelic LOF of PRG4. The principal non-genetic contributor is consanguinity (increases probability of homozygous inheritance). No environmental, infectious, toxic, or lifestyle causes; no known protective alleles or gene–environment interactions. Not applicable: GWAS loci, common susceptibility SNPs.

3. Phenotypes. Camptodactyly (congenital physical manifestation, ~100% — HP:0100490); non-inflammatory large-joint arthropathy with synovial hyperplasia (clinical sign, childhood onset, progressive, ~92–100% — HP:0100658/HP:0100763); coxa vara (radiographic, childhood, progressive, ~85% — HP:0005750); short femoral neck (~85%); pericardial effusion (variable onset, variable/less frequent — HP:0001644); pleural effusion (HP:0002102); reduced bone mineral density (HP:0004349). Labs: normal ESR/CRP (key distinguisher), non-inflammatory synovial fluid. Quality of life: progressive contractures and hip deformity impair mobility and daily functioning; cardiac tamponade/constriction is the severe-impact phenotype.

4. Genetic/molecular. Causal gene PRG4 (HGNC:9361; 1q31.1; OMIM 605602). Variant classes: predominantly frameshift and nonsense (truncating); ACMG class pathogenic/likely pathogenic; germline, homozygous; functional consequence loss of function (absent secreted protein). Allele frequencies: individually very rare/absent in gnomAD (private family mutations). No established modifier genes, disease-specific epigenetic signatures, or large chromosomal abnormalities.

5. Environmental. None causal. No toxins, infectious agents, or lifestyle factors. (Serosal effusions are sometimes clinically mistaken for tuberculous pericarditis — a diagnostic pitfall, not an etiology.)

6. Mechanism. See causal chain above. Core pathways: boundary-lubrication failure → friction → mitochondrial/caspase-3 apoptosis of superficial-zone chondrocytes; loss of synoviocyte growth suppression → hyperplasia; downstream ectopic hedgehog/BMP signaling in the model TMJ.

7. Anatomical structures. Primary: synovial joints (hip/coxa vara, knee, wrist, ankle, elbow, fingers, TMJ), articular cartilage, synovium, tendon sheaths. Secondary: pericardium, pleura (serosal), occasionally cardiac valves; skeleton (femoral neck, reduced BMD). Bilateral/symmetrical joint involvement. UBERON: 0002418 (cartilage), 0002103 (synovial membrane), 0000977 (pleura), 0002407 (pericardium).

8. Temporal development. Onset congenital (camptodactyly) → early childhood (arthropathy, coxa vara) → variable, sometimes adult-onset serosal disease. Course: chronic, progressive, non-remitting joint disease; serosal episodes may be episodic. Lifelong. The critical window for potential lubricin-replacement intervention is likely early, before irreversible cartilage loss.

9. Inheritance & population. Autosomal recessive; ultra-rare (no established prevalence); consanguinity-associated; complete joint penetrance, variable expressivity (cardiac); no strong sex bias; founder/private mutations in consanguineous families (South Asia, Middle East, Turkey, North Africa). Carrier frequency not established.

10. Diagnostics. Normal ESR/CRP; non-inflammatory, sterile, viscous synovial fluid; radiographs show effusion/synovial debris without erosions, coxa vara, short femoral neck, metaphyseal flaring; MSUS shows synovial hypertrophy/effusion without power Doppler; lubricin absent on blood/synovial-fluid immunoassay; definitive = PRG4 sequencing (WES/WGS/single-gene). Differential: JIA (key mimic), skeletal dysplasias (progressive pseudorheumatoid dysplasia, mucopolysaccharidoses), other familial arthropathies.

11. Prognosis. Progressive disability from joint deformity; constrictive pericarditis is the main mortality risk (manageable with pericardiectomy); normal cognition; near-normal lifespan with cardiac management. Main prognostic factor: presence/severity of cardiac involvement.

12. Treatment. No cure. Supportive: physiotherapy/occupational therapy, analgesia, orthopedic surgery (valgus osteotomy for coxa vara, joint replacement), pericardiectomy for constriction, valve surgery if indicated. Immunosuppressants/biologics are ineffective and should be discontinued once CACP is confirmed. Investigational: rhPRG4 replacement (preclinical). NCIT: physical therapy, orthopedic surgery, protein replacement therapy.

13. Prevention. No primary prevention. Genetic counseling and carrier/cascade testing in consanguineous families; prenatal/preimplantation genetic testing feasible once the familial variant is known. Tertiary prevention: regular echocardiographic surveillance for pericardial/valvular disease; bone-health monitoring (DXA).

14. Other species / natural disease. Orthologous gene: mouse Prg4 (NCBI Gene 56689). The Prg4⁻/⁻ mouse is an engineered (not natural) model; no well-established spontaneous CACP-equivalent natural disease in companion animals is documented in this knowledge base. The lubricin boundary-lubrication mechanism is evolutionarily conserved across mammals (bovine, equine, porcine lubricin all studied).

15. Model organisms. Primary: mouse (Prg4 knockout — mammalian genetic model) recapitulating synovial hyperplasia, superficial-zone chondrocyte loss/apoptosis, tendon/sheath pathology, and TMJ degeneration. Large-animal pharmacology: Yucatan minipig (rhPRG4 intra-articular efficacy). In vitro: bovine cartilage explants, synoviocyte cultures. Limitations: mice are born with normal joints and develop disease postnatally (age-dependent), and the human cardiac/serosal phenotype is not a prominent reported feature of the mouse. Resource: MGI (Prg4).

Limitations and Knowledge Gaps

1. No epidemiological denominator. Prevalence/incidence, carrier frequency, and population-specific rates are unknown; all data derive from small case series biased toward consanguineous populations.
2. Cardiac mechanism under-characterized. Why serosal/pericardial involvement is variable and sometimes adult-onset — and the basis of the rare mitral-valve association — is not mechanistically established.
3. Weak genotype–phenotype correlation. With predominantly null alleles, the determinants of variable expressivity (modifier genes, environment) are unknown.
4. rhPRG4 is preclinical only for CACP; no human CACP clinical-trial outcome data (NCT identifiers) were identified in this investigation.
5. Mouse-model gaps. The knockout does not clearly reproduce human cardiac serositis; camptodactyly is inferred from tendon-sheath pathology rather than directly modeled.
6. No omics in CACP patients. Patient transcriptomic/proteomic/metabolomic profiling is largely absent; mechanistic signaling data (hedgehog/BMP) derive from the TMJ mouse model, not human CACP tissue.
7. Bone-health phenotype newly emerging. Reduced BMD is reported in isolated cases (PMID: 42482035) but frequency and mechanism are undefined.

Proposed Follow-up Experiments / Actions

1. Establish an international CACP registry / natural-history cohort to define prevalence, phenotype frequencies (especially cardiac penetrance by age), and progression rates.
2. Advance rhPRG4 toward a first-in-human CACP trial — intra-articular dosing informed by minipig data (PMID: 28129516); define outcome measures (MSUS synovial hypertrophy, friction surrogates, joint function).
3. Validate the lubricin blood immunoassay (PMID: 25642942) as a first-line, low-cost diagnostic screen to shorten the diagnostic odyssey and curb inappropriate biologic use.
4. Deploy early PRG4 sequencing in any child with non-inflammatory, immunosuppression-refractory arthritis plus normal CRP/ESR and/or coxa vara — codify this as a diagnostic pathway/guideline.
5. Interrogate downstream signaling (hedgehog/BMP) in human CACP synovium/cartilage to test whether pathway inhibitors (e.g., BMP-receptor kinase inhibitors) could serve as adjunct therapies, building on TMJ-model findings (PMID: 26534931).
6. Systematically assess cardiac and bone health (serial echocardiography; DXA) across cohorts to quantify constrictive-pericarditis risk and the newly reported low-BMD phenotype.
7. Explore gene/cell-based correction (AAV PRG4 delivery, or lubricin-secreting cell therapy) as a durable alternative to repeated protein replacement.

Report compiled from 11 confirmed findings and 37 reviewed publications over 5 investigation iterations. Evidence types are indicated per citation (human clinical, mouse/model organism, in vitro, large-animal preclinical). Primary literature PMIDs are provided throughout; direct abstract quotes are used verbatim to support key mechanistic and clinical claims.